Company news

Allarity Therapeutics, Inc. (NASDAQ:ALLR) news

Allarity Therapeutics, Inc. news releases on 6ix. Latest, Sep 13, 2024: Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing…

Allarity Therapeutics, Inc. (NASDAQ:ALLR) news

Press releases — page 2

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Allarity Therapeutics to Present at Biomarkers 2024

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

Allarity Therapeutics to Present at Biomarkers Europe 2023

Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology

PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib

Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering

Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

Allarity Therapeutics Announces Appointment of New Auditor

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.

Allarity Therapeutics Announces Executive Leadership Transition

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

Allarity Therapeutics Reports First Quarter 2022 Financial Results